Markus Hinder
-
- Heart Failure Treatment and Management 6
- Cardiac electrophysiology and arrhythmias 5
- Atrial Fibrillation Management and Outcomes 4
- Blood Pressure and Hypertension Studies 3
- Health Informatics top 10%
-
- Intellectual Property and Patents 3
- Internal Medicine top 10%
-
- Pharmaceutical Economics and Policy 8
- Innovation Policy and R&D 7
-
- Biotechnology and Related Fields 7
- Co-authors
- Alexander SchuhmacherOliver GassmannDominik HartlThomas LangenickelParasar PalMichael KussCharlotte WagnerBernhard K. Krämer
- Cited by
- Cardiology and Cardiovascular MedicineHealth InformaticsManagement of Technology and Innovation
- Journals
- Drug Discovery Today (9 papers)The Journal of Clinical Pharmacology (4 papers)Clinical Pharmacology & Therapeutics (3 papers)
- Partner nations
- GermanySwitzerlandUnited States
In The Last Decade
Markus Hinder
47 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 138
- Cardiology and Cardiovascular Medicine 302
- Health Informatics 15
- Management of Technology and Innovation 76
- Internal Medicine 34
- Endocrinology, Diabetes and Metabolism 127
Countries citing papers authored by Markus Hinder
This map shows the geographic impact of Markus Hinder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Hinder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Hinder more than expected).
Fields of papers citing papers by Markus Hinder
This network shows the impact of papers produced by Markus Hinder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Hinder. The network helps show where Markus Hinder may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Markus Hinder, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 9 | |
| 2 | 2023 | 34 | |
| 3 | 2022 | 22 | |
| 4 | 2021 | 36 | |
| 5 | 2021 | 18 | |
| 6 | 2021 | 7 | |
| 7 | 2020 | 6 | |
| 8 | 2018 | 3 | |
| 9 | 2018 | 2 | |
| 10 | 2018 | 39 | |
| 11 | 2016 | 21 | |
| 12 | 2016 | 186 | |
| 13 | 2016 | 39 | |
| 14 | 2010 | 18 | |
| 15 | 2006 | 25 | |
| 16 | 2006 | 6 | |
| 17 | 2000 | 1 | |
| 18 | 1999 | 3 | |
| 19 | 1998 | 10 | |
| 20 | 1998 | 35 |
About Markus Hinder
Markus Hinder is a scholar working on Cardiology and Cardiovascular Medicine, Management of Technology and Innovation, Economics and Econometrics, Endocrinology, Diabetes and Metabolism and Reproductive Medicine, having authored 48 papers that have together received 1.1k indexed citations. Recurring topics across this work include Pharmaceutical Economics and Policy (8 papers), Innovation Policy and R&D (7 papers), Biotechnology and Related Fields (7 papers), Heart Failure Treatment and Management (6 papers), Cardiac electrophysiology and arrhythmias (5 papers), Atrial Fibrillation Management and Outcomes (4 papers), Blood Pressure and Hypertension Studies (3 papers) and Intellectual Property and Patents (3 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (302 citations), Health Informatics (15 citations), Management of Technology and Innovation (76 citations), Internal Medicine (34 citations) and Endocrinology, Diabetes and Metabolism (127 citations). Markus Hinder has collaborated with scholars based in Germany, Switzerland and United States. Frequent co-authors include Alexander Schuhmacher, Oliver Gassmann, Dominik Hartl, Thomas Langenickel, Parasar Pal, Michael Kuss, Charlotte Wagner, Bernhard K. Krämer, Surya Ayalasomayajula and Fan Yang. Their work appears in journals such as Drug Discovery Today, The Journal of Clinical Pharmacology, Clinical Pharmacology & Therapeutics, Journal of Translational Medicine and Nature Reviews Drug Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.